橡アロマセラピー症状別処方例.PDF

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "橡アロマセラピー症状別処方例.PDF"

Transcription

1 E 100ml m 10ml 100ml l g ml ml

2 2 10ml ml A ml A E 100ml ml 100ml ml 6ml

3 ml ml CT ml ml ml ml ml

4 ml mg 10mg No mg mg 1 320mg ml ml

5 ml 100ml 100ml ml mg ml mg mg 5

6 40mg No mg mg mg mg ml 100ml ml

7 ml ml ml ml ml CT

8 CT1 50mg 80mg 10mg 30mg 1.2g 20mg 40mg mg mg ml CT ml ml ml

9 ml ml ml ml ml ml ml ml

10 ml ml ml 15 10ml EU 10

11 ml ml mg 50mg 20mg No mg ml mg

12 12 CT CT 1 ml ml 20ml 100ml ml 2 100ml 100ml

13 ml ml ml ml g E 0.5g 40ml 100ml ml 250ml 250ml 250ml

14 20ml 100ml ml CT ml ml ml ml CT

15 15 10ml 10ml E 100ml ml 100ml 100ml ml 100ml ml ml mg 4 10 CT CT3

16 ml ml 10ml No ml 1 30ml 320ml ml ml ml 10ml CT3

17 mg 25mg 50mg No mg mg 20mg No mg 320mg ml 6ml 50ml mg 50mg 50mg 4g mg ml 100ml 20ml 150ml CT1 60mg 20mg 40mg No mg

18 mg CT ml ml ml ml CT ml ml ml mg 20mg 18

19 20mg 20mg No mg 320mg ml ml ml ml ml ml ml ml

20 10ml l ml 4ml ml ml CT ml 10ml E 100ml ml 100ml 100ml 3 20

21 21 CT CT ml 50mg ml mg

22 25mg 40mg No.0 CT2 50mg mg mg 50mg No.0 300mg mg mg

23 23 C T CT CT CT mg 3 3 5

24 ml mg 30mg 20mg 40mg 10mg 20mg 1.2g CT 25mg 60mg ml 4ml CT1 4ml ml mg CT2 25mg CT1 60mg No.0 320mg CT1 4ml ml mg ml

25 10 10ml CT3 5 10ml ml CT ml CT ml

26 ml ml 8ml ml ml ml 1.2g 10 10ml ml 100ml mg 30mg 40mg 60mg 20mg 40mg 10mg 20mg 1.2g 2g ml 100ml 100ml mg 30mg 26

27 30mg 50mg 20mg 60mg 1.2g 2g mg 40mg No mg mg ml ml 18ml ml 18ml ml

28 ml ml ml ml 28

29 ml ml ml 100ml ml

30 ml ml ml ml ml ml ml ml ml E 0. 30

31 CT CT ml 30ml ml ml ml ml ml ml 6ml CT2 100mg 150mg 4g 30 31

32 50mg mg ml mg CT2 20mg No mg mg 60mg 25mg No mg ml ml mg

33 20ml ml mg 20mg 2g mg 1 150mg mg 25mg 25mg No mg 25mg 1 350mg mg

34 E ml 6ml ml ml ml ml

35 ml 4ml ml 100ml mg 40mg No mg 320g ml mg 30mg 20mg No mg mg mg CT ml mg CT1 40mg 40mg 20mg No mg 2 35

36 ml ml ml 4 5 CT ml

37 30ml 20ml 20ml No ml ml mg ml ml ml l ml ml ml 10ml 50ml ml 8ml

38 ml ml ml ml ml ml

39 10ml ml ml ml ml CT3 39

40 ml ml ml CT ml

41 CT CT1 30ml ml 100ml 50ml

42 CT1 100ml mg CT1 40mg 40mg 20mg No mg ml ml ml 2 3 6ml 42

43 mg ml ml ml mg 30mg 30mg 50mg 4g 14 40mg CT2 50ml 100ml 50ml ml mg 30mg No

44 55mg mg ml 100ml ml 100ml ml ml ml ml ml

45 ml ml ml ml ml mg 20mg 30mg 30mg 20mg No mg ml

46 ml ml 6 1 CT2

47 47 CT ml mg 20mg 10mg 20mg 40mg 10mg ml mg ml 4ml 4ml 60ml mg 50mg 50mg 20mg 100mg

48 m mg 30mg 40mg 60mg 1.2g 20mg 40mg mg 50mg 30mg No mg mg mg 20mg 80mg CT 100mg 4g mg 20mg 20mg CT1 40mg No mg 3 48

49 CT CT CT 100mg 4g mg mg mg CT 300ml 200ml mg 40mg CT1 20mg No mg ml 100ml

50 ml ml 10ml 20ml 100ml CT1 10ml ml ml 2 3 4ml 10ml 100ml ml 100ml ml ml

51 ml 100ml 50ml mg CT1 50mg 30mg 320mg mg ml ml 100ml 50ml

52 ml ml 50ml 50ml g 10ml 50ml ml mg No mg mg 3 52

53 53 320mg ml 3 4 1/4 1 10ml ml ml

54 ml mg 10mg 20mg 30mg 20mg No mg mg 50mg ml ml ml ml

55 55 CT ml CT ml ml 20ml 100ml ml 100ml 2 100ml ml 2 100ml

56 CT ml mg mg CT 20mg 30mg No mg ml 2 100ml mg ml mg 30mg 20mg No mg mg CT 20 56

57 100ml ml O ml 6ml ml ml ml 57

58 ml 10ml 50ml ml ml ml A ml A CT 58

59 ml CT ml

60 ml ml ml ml ml

61 10ml ml ml ml ml ml ml

62 ml ml mg 50mg 300mg No mg ml

63 ml ml ml ml 63

64 ml ml 3 4 CT

65 mg ml mg

66 ml ml 2 3 6ml mg ml ml

67 ml ml ml ml ml 2 67

68 ml ml

69 ml ml ml ml ml 100ml mg 20mg 10mg 30mg 40mg mg 30mg ml 69

70 mg ml mg mg 40mg No.0 60 CT2 50mg 320mg CT CT mg 80mg 4g mg 18 40mg ml 300ml 500ml 70

71 ml 30ml mg 30mg 10mg 20mg 50mg 70mg 15mg 30mg ml ml ml CT2 80mg 4g 30 40mg 71

72 100mg mg CT2 300ml 200ml CT2 70mg 30mg 20mg No mg ml mg 35mg 15mg No mg

73 2 1 CT CT ml ml 10ml 100ml ml ml

74 74 10ml 100ml ml mg 35mg 15mg No mg CT3

75 ml CT CT2 10ml 100ml l

76 ml 100ml mg 25mg No mg mg mg 100mg 50mg 2g ml

77 77 10ml ml

78 mg 50mg 100mg 4g 18 50ml ml 100ml 100ml mg CT1 40mg 20mg No mg mg 20mg No mg mg ml 6ml 50ml

79 CT CT ml mg 35mg 15mg No mg ml

80 ml mg ml ml ml CT ml A 10ml 80

81 mg 50mg 300mgNo mg g E 0.5g 40ml 100ml ml 250ml 250ml 250ml ml 100ml ml

82 ml ml

83 1 247 CT 30ml ml 100ml 2 100ml ml

84 10ml ml ml CT ml 10ml 100ml ml 10ml 10ml E 100ml 84

85 ml ml ml ml ml ml 85

86 6ml ml ml mg 50mg 20mg No mg ml ml mg 20mg 30mg 30mg 20mg No mg

87 mg ml ml ml

88 ml ml ml 50ml 20ml No ml ml

89 CT CT ml ml ml ml ml CT ml

90 ml ml l ml ml 10ml 50ml ml ml ml

91 ml ml ml ml CT 91

92 ml ml ml ml ml ml 92

93 50ml 2 50ml [ ] ml 10ml 100ml ml ml 3 4 CT ml ml 93

94 ml

95 ml ml ml ml ml ml ml ml

96 96 10ml CT CT CT CT ml

97 ml CT1 4ml ml mg l ml CT ml ml ml ml

98 ml CT ml CT

99 99 10ml CT1 CT ml CT

100 ml ml ml 4ml 80ml ml ml ml CT

101 CT ml mg ml 10ml 100ml ml

102 ml CT ml mg No mg 1 35mg mg ml ml CT2 10ml ml

103 ml ml ml 3 2 CT CT ml 10ml ml

104 ml ml ml ml ml

105 ml ml 6ml ml ml ml ml

106 ml 10ml mg 25mg 50mg No mg mg ml ml

107 mg 20mg 80mg 4g 18 CT 100mg mg 20mg 20mg CT1 40mg No mg ml mg 50mg CT150mg 50mg 4g 20 25mg

108 ml ml CT[ ] ml ml ml mg 80mg 20mg 50mg 1.2g 10mg 20mg

109 mg 40mg 10mg No mg mg [ ] CT2 10ml 100ml ml 4ml

110 18ml ml ml ml ml ml ml ml 50ml

111 111

Microsoft Word - 表紙資料2-4

Microsoft Word - 表紙資料2-4 (1) / 130 g 25 g 520% 170 g 30 g 560% 70 mg 600 mg 11.6% 0 10.5 mg 0% (1) (2) / 50100 g 25 g 200400% 50100 g 30 g 167333% 5001000 mg 600 mg 83167% 1020 mg 10.5 mg 95190% (2) / (1) 45.6 g 30 g 152% (2)

More information

untitled

untitled -- -- -3- % % % 6% % % 9 66 95 96 35 9 6 6 9 9 5 77 6 6 5 3 9 5 9 9 55 6 5 9 5 59 () 3 5 6 7 5 7 5 5 6 6 7 77 69 39 3 6 3 7 % % % 6% % % (: ) 6 65 79 7 3 36 33 9 9 5 6 7 3 5 3 -- 3 5 6 76 7 77 3 9 6 5

More information

untitled

untitled NO. 2007 10 10 34 10 10 0570-058-669 http://www.i-nouryoku.com/index.html (40 ) () 1 NO. 2007 10 10 2.2 2.2 130 70 20 80 30 () () 9 10 () 78 8 9 () 2 NO. 2007 10 10 4 7 3 NO. 2007 10 10 40 20 50 2 4 NO.

More information

23 3 11 14 46 9.0 7 10m 40.1m 15,883 2,681 25 4 10 39 40 800 180 24 2425 22 21 24 5 3 21 24 10,899 20,472 13,723 33,007 667 400 79,167 8,620 11,694 10,089 25,131 690 215 56,439 13,614 20,897 15,200 32,213

More information

14 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 20 0 0 0 0 0 0 0 0 0 0 0 0 21 0 0 0 0 0 0 0 0 0 0 0 0 22 0 0 0 0 0 0 0 0 0 0 0 0 23 0 0 0 0 0 0 0 0 0 0 0 0 24 0 0 0 0 0 0 0 0 0 0 0 0 25 0 0 0 0 0 0 0 0 0

More information

I

I I II 1 2 3 4 5 6 7 8 9 10 11 Rp.1) 50mg 3 3 14 Rp.2) 2.5mg 2 14 Rp.1) 2.5mg 3 2 2:1 14 Rp.) 15g 1 3 28 Rp.2) 50 600mg 1 2 28 12 Rp.1) CR 20mg 1 1 1 14 Rp.2) R 200 1 2 14 Rp.3) 3 1 3 14 Rp.1) 2.5mg 0.4

More information

2 / 7

2 / 7 1 / 7 1.30 1.301.00m 2.00 2.001.00m 1.70 1.701.00m 2.4 2.41.0m 2.0 2.01.0m 1.08 1.20.9m 1.08 1.20.9m 2.5 2.51.0m 2.5 2.51.0m 0.9 1.00.9m 1.44 1.60.9m 2 / 7 ml ml 3 / 7 4 / 7 ) 5 / 7 6 / 7 0798-56-1710

More information

2 (1) (2) SCI 2 SCI 2 24 2 12 2

2 (1) (2) SCI 2 SCI 2 24 2 12 2 2004 (1) (2) (2) (3) (1) 1 (2) (3) 2 (1) (2) SCI 2 SCI 2 24 2 12 2 100% / 16 2002 2003 http://lin.lin.go.jp/alic/month/dome/1997/nov/chousa.htm (05 612 1315 1618 1922 2329 3039 4049 5059 60 ) =10 b g 1

More information

-51-

-51- -50- -51- 11 3 28 8 1 24 7 2 36 10 1-52- -53- 1 2-54- 6 1 2 3 4 5 6 6 1 19 5 200 300ml 20 6 400ml -55- -56- 10-57- 4 2 20-58- 2,500-59- -60- -61- 2-62- 6 3-63- 9 68 1 6-64- 3-65- 4-66- 5 6-67- -68- 1 1

More information

2006年3月8日

2006年3月8日 18 21 1990 2004 2 2005 14 15 2004 1990 2005 2003 300 7 2 1 2005 1972 100 40 6 1972 2004 197 6,500 2004 21 59 100 65 2007 5 2005 30 1.8 535.89 348.33 187.56 2006 2006 5 1 30 1 30 46 46 1 46 1000kl 4 1 100kl

More information

8 8 0

8 8 0 ,07,,08, 8 8 0 7 8 7 8 0 0 km 7 80. 78. 00 0 8 70 8 0 8 0 8 7 8 0 0 7 0 0 7 8 0 00 0 0 7 8 7 0 0 8 0 8 7 7 7 0 j 8 80 j 7 8 8 0 0 0 8 8 8 7 0 7 7 0 8 7 7 8 7 7 80 77 7 0 0 0 7 7 0 0 0 7 0 7 8 0 8 8 7

More information

肝臓病教室201207v2配布用.pptx

肝臓病教室201207v2配布用.pptx 24 7 28 5 C C C C 11 1 vs 2 vs 1 0 1 600-1000mg 3-5/ 24,48 2448 12 1 1500-2250mg 6-9/ () 1 600-1000mg 3-5/ 0 24 88.1% 0 20 40 60 80 100 C ALT, GPT 30 34.4% ALT, GPT 0 20 40 60 80 100 2 , 2 3 1 1-100% 0

More information

ml ml ml mg ml ml mm mm mm mm mm mm mm mm mm mm mm ml mmhg mmhg ml Acetylcholine ml mg mm mm mm mm mm mm ope ++ Uribe Davis S H S S : : : : : : : : : G

More information

評価結果報告書の概要版(平成20年度)

評価結果報告書の概要版(平成20年度) 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76

More information

MAWGD08Y 5 5 5 5 5 5 6 5 5 6 6 7 5 6 7L 55L 5L 0L 8L 0.0 6.0.0.0 0.5 8 7 0 0 96ml 7ml 60ml 0ml ml 8ml 7ml 0ml 0ml ml 96 7 60 0 6ml ml 0ml 7ml ml 8ml 7ml 0ml 0ml ml 8 7 0 0 5 6 7 5 6 5 (0)890-750

More information

:,, : - 7 -

:,, : - 7 - 31 ~ ~ - 6 - :,, : - 7 - (),,,,,,; ~ ~ *1 *2 6,,,~,,~ - 8-32 ,, ( );( ),,,,,, ~ ~ ~,,,, (),,,,, - 9 - 33 ~*~ ~~ ~, ~ ~ ~ ~ ~, ~~,,,, - 10 - BCG () g ) BCG BCG,, 34 ,,,, (),,,,,,,,,,,,,, () ( 3 90 [7 6

More information

d-00

d-00 283-0105 298 TEL. 0475-76-0839 FAX. 0475-76-0838 400g 300 4950399167708 14 220g 300 4950399066780 Page 1 300g 200 4950399066766 100 400g 300 4950399167722 350g 160 4950399066735 100 600g 350 4950399167685

More information

2

2 1 2 119 119 5 500 1 30 102 1 113 3 4 120 2 3 113 5 230 1 1 3 4 5 6 7 8 1 support@kansen.sakura.ne.jp 2 9 3 ( ) 10 11 12 4 1. 2. 3. 4. 13 5 14 15 16 17 18 19 [ ] [ ] 20 [ ] [ ] [ ] 21 22 [ ] 23 < > < >

More information

1 8 7 30 8 15 12 11 30 12 15 18 18 00 18 30 10 15 19 30 9 45 13 45 11 30 18 9 15 30 30 1 1 2

1 8 7 30 8 15 12 11 30 12 15 18 18 00 18 30 10 15 19 30 9 45 13 45 11 30 18 9 15 30 30 1 1 2 7 19 20 30 1 1 8 7 30 8 15 12 11 30 12 15 18 18 00 18 30 10 15 19 30 9 45 13 45 11 30 18 9 15 30 30 1 1 2 3 10 11 12 13 4 6 6 14 15 16 17 18 5 1 1 6 2 7 () 8 9 10 - 1 - - 2 - - 3 - - 4 - - 5 - - 6 - -

More information

レイアウト 1

レイアウト 1 1 3 6 7 8 3 6 7 8 g mg 6 1 16 16 18 16 13 138 13 16 1 11 8 78 8 17 9 9 g mg 18 13 1 1 1 99 6 3 36 3 3 8 1 18 18 18 16 16 1 1 g mg 1 1 13 13 1 11 11 g mg 8 6 g 1 g mg 93 38 9 93 8 8 176 1 1 1 1 11 18

More information

MAWN8UP MAWN7UP MAWN6UP 3 3 3 5 4 3 3 3 3 4 3 3 4 4 3 3 4 4 3 3 4 4 3 3 4 3 3 4 3 3 3 4 3 4 5 3 3 4 5 3 4 3 5 4 3 5 6 6 3 4 5 6 7 54 50 40 30 58 50 40 30 6 50 40 30 8.0 7.0 6.0 5.0 4.0.0 0.5 3 9

More information

Digital Photo Professional Ver1.6(Windows)

Digital Photo Professional Ver1.6(Windows) Windows CT1-5193-000 CANON INC. 2005 J 1 2 3 4 s s s 1 1 s s s s s 1 1 a s s 1 s s 1 2 s a 1 s a 2 3 1 1 s a a 2 a 3 a s s 1 a a s a s s 1 s s 1 2 3 s 1 1 a 2 a 1 a s 2 3 1 1 s a 2 1 3 1 s a 2

More information

untitled

untitled 1.4 特 許 状 況 - 1 - - 2 - 1.5 起 原 又 は 発 見 の 経 緯 及 び 開 発 の 経 緯 FCT CT RH ... 1.5-1... 1.5-1... 1.5-1... 1.5-1... 1.5-2... 1.5-2... 1.5-2... 1.5-3...1.5-4... 1.5-5 i 10mg FCT 1 1 6 15 5mg CT 1 1 2 6 4mg CT

More information

NIHSS score p NIHSS score p149 4 p g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml

NIHSS score p NIHSS score p149 4 p g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml NIHSS score14 1 400 1 p149 1 25 20 NIHSS score14 15 10 5 2 p149 4 p151 0 0.8 g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml 1 2 148 149 3 2 3 A B C 4 D 2 A B C A C 1 Ogata T et al J Neurol Sci 272 83 86 2008

More information

[ml] 180 160 140 120 100 80 60 40 20 0 Cumulative biogas production [ml/mg-input VS] 0 10 20 30 40 50 60 [] 1 0.8 0.6 0.4 0.2 0 dog food PLA foam 0 10 20 30 40 50 days RUN1-1 RUN1-2 RUN2-1 RUN2-2 RUN3-1

More information

<836C83628367834A8374834692B2B895F18145706466>

<836C83628367834A8374834692B2B895F18145706466> 1. 30 5 500 2 7 100 2 10 100 2007 4 1 7,200 6,800 7 NPO 1,200 1 12 15 2 1.5 0.5 30 2 24 5 27 16.8 28 2.3 10,500 / 3 3,800 117 2 3 6 6,000 1 1 1 2 2006 1 6, 000 + + 8 30 17 00 7.5 13 2 B2 2. 50 2 3 1 1

More information

untitled

untitled - 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - - 10 - - 11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17 - - 18 - - 19 - - 20 - - 21 - - 22 - - 23 - - 24 - - 25 - - 26 - - 27 - - 28 - - 29 - - 30 -

More information

152273335 1 123 11531 2 5 24 31 2 154301482 1551 JAS 100 2000 105 1101 1 2JAS 1-2 1

152273335 1 123 11531 2 5 24 31 2 154301482 1551 JAS 100 2000 105 1101 1 2JAS 1-2 1 152273335 1 123 11531 2 5 24 31 2 154301482 1551 JAS 100 2000 105 1101 1 2JAS 1-2 1 JAS 1-2 1-2 112 13 1-11-13 100870mg 100830mg11000 1100020.002 2 50 100 2 100 500 2 100 109252165 4514782 7 2.0kg 2-19220.05kg0.2kg

More information

Taro10-mizushima01.PDF

Taro10-mizushima01.PDF - 1 - ATAGO N- % % g % g % g % g % g % g Brix% g g ml ml mgm / l ml mg mol/l mol/l mol/l ph NaSO mol/ l ml / g mg mg ml mol/l ml ml L- L- FIBE-MINI FIBE-MINI % % FIBE-MINI % g % g % g % C mg mg mg

More information

<4D6963726F736F667420576F7264202D2030373130313683708375835283818C8B89CA816992B882A282BD8EE582C882B288D38CA982C68D9193798CF092CA8FC882CC8D6C82A695FB816A817995CA9359817A>

<4D6963726F736F667420576F7264202D2030373130313683708375835283818C8B89CA816992B882A282BD8EE582C882B288D38CA982C68D9193798CF092CA8FC882CC8D6C82A695FB816A817995CA9359817A> 1 18 12 27 2 3 18 12 27 18 12 27 4 18 12 27 18 12 27 5 18 12 27 6 7 18 12 27 8 18 12 27 9 18 12 27 10 18 12 27 18 12 27 18 12 27 18 12 27 11 12 18 12 27 18 12 27 13 14 18 12 27 18 12 27 15 16 17 18 12

More information

EL-G37

EL-G37 EL-G37 A A A A A A A A A A A A A A GT F543210A CE CA 4 00. 00 23.80 2 015.6250 77.14286 96. 91. 102. 25. 9. 1 700. 2 720. 2.5 7. 20. 25. 220. 400. 4 096. 4.685 0.084 M 125. M 28. M 85.

More information

M.D.I VDT 29. (1)

M.D.I VDT 29. (1) 5. 5. 5.1 (1 (2 (3 (4 3040 5.2 32 1 1 43 2 44 3 45 13 14 1) 4 45 2 5 46 6 47 7 66 2 8 26 2 1 32 2) 1 2 53 3 39 4 40 5 56 6 29 7 38 8 22 9 22 3 48 2 29 5. 17 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14.

More information

2

2 1 3 11 21 2 3 28 42 33 12 31 11 4 21 46.5 30.0vol 30 36 16 DXNs 46 19 B 42 22 5 0.44 10 15 20 20 1.5 1.5 0.1 0.37 6 4.5 1.7 16 1.5 1.5 4.5 1.5 7 3.6 4.4 12 8 1.5 9 46 19 19 10 500ml 11 33 3.6 3.9 12 2.1

More information

untitled

untitled 61 62 18 19 10 20 21 22 63 23 24 64 65 EU 100 66 ? ( )? 1999 2 22? 1 1? 67 9 0 6 8 9 1 1 1 Java? 1 2 3 5 4 9 8 2 3 5 II 4 4 4 5 II 1 I 68 II (?) 9 2 2 1 1 2 2 3 4 4 5 5 5 3 4 11 2 1 2 69 10 2F 2F 6 2 11

More information

untitled

untitled ( 1,000 1 0562-92-8317 0562-93-8105 12 1000 133015303/25 10 700 90011303/30 100 0 100011303/25 1 30 2 30 3 1 12 5 3000 7000 9001130 5/135/276/37/88/5 1 2 35 2 10 5 3000 5000 3 9001130 6/86/227/68/249/21

More information

arakidonsan.rtf

arakidonsan.rtf DHA (ARA) ARA DHA 50 DHA 20 DHA( ) γ 300 mg 170 mg 150 mg 78 mg 57 mg 3,200 mg 2,300 mg 1,700 mg 1,700 mg 1,700 mg β- E FAO DHA( ARA) DHA 2ARA 1 DHA 70mg 100g 35mg 100g 6 6 63 EPA DHA 63 6 EHA DHA 50 WEB

More information

104 100 60 9,195,336 409 0.004 24 8 31 9,025,983 568 0.006 2012 8 31 6,634,686 956 ( 0.014 ) 2 2011 8 26

104 100 60 9,195,336 409 0.004 24 8 31 9,025,983 568 0.006 2012 8 31 6,634,686 956 ( 0.014 ) 2 2011 8 26 25 25 3 5 MMR 1 104 100 60 9,195,336 409 0.004 24 8 31 9,025,983 568 0.006 2012 8 31 6,634,686 956 ( 0.014 ) 2 2011 8 26 2012 8 31 1,032,660 132 ( 0.013 ) 3 2010 6 11 3 11 15.4 1 1 ( ) 12 2 2 3 ER ) (

More information

第27回創業・IT等ワーキング・グループ 資料2-5

第27回創業・IT等ワーキング・グループ 資料2-5 1. 2 1 2 1 3 4 EU EU 5 3 4 5 2 6 7 8 9 6 7 8 http://www.moj.go.jp/content/000047175.pdf 9 http://www.moj.go.jp/shingi1/shingi04900058.html 3 10 11 12 13 14 10 11 12 13 () http://www.moj.go.jp/content/000104766.pdf

More information

untitled

untitled ~ ~ ~ ~ ~ 22 14 10 50cm 2124 15 21 29.5 11, 12 12 20 4040 10 60 60 10 20 20 11 ç ç çç 6070 ç ç çç p. ç çç 4.5cm2.5cm 25 http://www.crdc.gifu-u.ac.jp/edsoftol/water/

More information

からだにeヘルシーレシピ 高血圧

からだにeヘルシーレシピ 高血圧 We b e 3,5 00 7day 1. 2. & 3. 1 C O N T E N T S 2.6 0 1 0 5 0 7 1 0 9 17 2 2 2 3 CHECK&POINT! 2 5 24 1 2 7 e 2 9 e 3 1 webe 3 3 6 12 18 24 6 16 16g 111 1 6 1 2010 2010 18 20 3,970 18 1 400 2.6 01 02 140mmHg

More information

137

137 136 137 16 12 16 17 3 18 138 8 125 144 269 9 125 144 269 10 125 144 269 11 125 144 269 12 125 143 268 13 124 146 270 14 124 147 271 15 124 149 273 16 124 149 273 17 124 152 276 4 1 3 3 3 3 3 3 8 2,641

More information

CW3_AX056A01.indd

CW3_AX056A01.indd 165 166 167 168 169 170 A 171 172 173 174 175 176 177 178 179 ritalin http://www.ncnp.go.jp/nimh/yakubutsu/drug-top/data/ researchjhs.pdf 180 mg mg http://www.novartis.co.jp/product/rit/te/te_rit. html

More information

無印良品 2012 自転車 カタログ

無印良品 2012 自転車 カタログ 26 897895321,000 140cm 76.0cm 16.0kg H LED 3 263 897896025,000 140cm 76.0cm 16.5kg H 3 LED 20 8978984 8978977 19,800 134cm 73.0cm 15.0kg LED 2620 2620 8486656550 5536207483 14512372,100 8279999840 26 77342561,417

More information

Microsoft Word - 観光と食 2・3 食品添加物 vs. 質の事業.doc

Microsoft Word - 観光と食 2・3 食品添加物 vs. 質の事業.doc 2 1. Ø 90 15 100 130 3 Ø Ø Ø Ø Ø ph Ø Ø ph Ø Na Na CMC OKINAWA UNIVERSITY 1/13 Na Na V.C ph ph Ø C g mg Ø ml g Ø Ø V.C g C mg 50kcal g Ø OKINAWA UNIVERSITY 2/13 Ø Ø Na Ø Ø Ø Ø Ø Ø Ø 1. 2. 3. 4. Ø OKINAWA

More information

1 2 3 4 5 68g 9g 2g 0.2mg 0.8mg 316kcal 316cal 326kcal 326cal 6 010 3035 15 5355 30 120 20 7 8 9 10 11 () () () 12 1 3 1 5 1 80kcal 20 30 20 30 1 9 7.5 13 7.58.5 910.5 1213.5 11.512.5 14 15 79 23 1520

More information

001-007 扉・口絵・目次

001-007 扉・口絵・目次 1 6 6 7 1 a a a a 2 a a a 3 4 5 a 6 7 8 9 10 a 11 a a a 12 13 14 15 a 16 17 18 19 20 21 22 23 24 b b 25 b 26 27 aa 28 r r 29 a s d f 30 b b 31 32 33 1 34 35 36 37 38 6 39 6 40 41 42 43 44 45 7 47 48

More information

untitled

untitled . 23 3 2 1 2 3 21 21 22 9 1 23 18 4 5 6 5 40 20 7 1 1 8 9 10 11 12 50cm 13 10 11 14 2011 3 11 15 16 ml mm tel 079-557-0039 & fax 079-557-1888 17 248-240- 98-48- 170-98- 98- ml 85-1,085-18 19 20 21 22 23

More information

22

22 2015 75 7074 6569 2064 26470 21 22 4,060 1,330 23 24 15,000 80 24,600 15,000 15,000 24,600 15,000 24,600 15,000 24,600 37,200 145 520 383 44,400 25 26 280 160280 280 346 160 80 160 37,200 24,600 15,000

More information

0.02ml IgE RAST MAST CAP 2

0.02ml IgE RAST MAST CAP 2 ( ) 1 0.02ml IgE RAST MAST CAP 2 3 1963 30 4 1986 20 39 IgE 30% 1988 54.7% IgE 47.6% 1990 892 IgE 27% 12% 1995 2379 1995 8 15 1996 1 12 2335 98.5% 2335 24 61 47 44.0 1 1) 2335 613 26.3% 2 5 613 43.4 44.2

More information

1

1 1.... 1 2.... 1 3.... 2 4.... 3 5.... 4 1)...5 2)...10 3)...14 4)...15 5)...16 6.... 18 7.... 19 8.... 20 1... 25 2... 26 3... 27 1. ( ) 2. - 1 - 3. 1) 2) 3) 6 ( ) 5 4) - 2 - 4. 1) PIO-NET 2) ( 1) (1)

More information

2015taisetumatome.rtf

2015taisetumatome.rtf B B B( ) B3 - B3 1 3g 1/3 B 1. B1() B1() 2. B2() B2() 3. B5() B5() 4. B6() B6()( ) 5. B12() B12() 6. 1q60 160m 50m 50m 20m 8520 80 10 64 5075 30 80 B B 1 30 BB BC EPA . ?? 6 C E C 1 30 1 0.4mg4

More information

2011 2011 2011 100/m 0.003/ 0.0005 / 0.01/ 0.01 / 0.01/ 0.05 / 0 0.0003 0.00005 0.001 0.001 0.001 0.005 0 0.0003 0.00005 0.001 0.001 0.001 0.005 0 0.0003 0.00005 0.001 0.001 0.001 0.005 0 0.0003 0.00005

More information

134,000 0 0 0 RC 6!! 2 7 1 1,212,052 134,000 1,346,052 1/1 No.2734-2

134,000 0 0 0 RC 6!! 2 7 1 1,212,052 134,000 1,346,052 1/1 No.2734-2 2015.1.8 2734 SAA EU 1 954,000 1,083,000 2 5 23 24 2 22 IM 3 15 IM 12 134,000 0 0 0 RC 6!! 2 7 1 1,212,052 134,000 1,346,052 1/1 No.2734-2 57 11/5 1 27 5 No.2734-3 No.2734-4 No.2734-5 53 3 2 1 MU MU 12

More information

- 1 - 15 2030 4 21 21-2 - 2 1 21 21 4 22 31 10 5 26 ( JA ) - 3 - 4 21 7 9 9 34 1,386 1,003 94 58 1,155 60 25 33 1 3 2-4 - 12 17 60 7 7 12 H1217 4 7 30 34 19-5 - - 6 - (BMI*18.5) 20 15.2%30 8.% 20 86.4%30

More information

Taro9-医薬品目次2012-1.PDF

Taro9-医薬品目次2012-1.PDF 5 0.1% 11 250mg 10 20mg 10 5ml 19 0.05% 13 1.25mg 10 1%5ml 19 10mg 10 0.2%100ml 18 25%50ml 9 2mg 17 5%250ml 9 20%25g 20 500 g 11 4 10g 20 Cap150mg 1 200mg 0 Cap90mg 5 20mg 10 10% 5 18 10mg 10 3%30g 20

More information

本文/一般演題_吉田

本文/一般演題_吉田 184 quality of lifeqol mmhg Hb gdl CA Uml Niveau Hb Hb gdl RCC CT MRI T 185 CT A B MRI A:T B:T Douglas red spot S ml RCC 186 A B mg CAUml S MRI A B 187 188 S mg Sampson JA. Intestinal adenomas of endometriosis

More information

21 8 20 70 1 1 2 1 1 20 12 22 16201835 2 21 1 21 15001910 3 21 2 23 15001750 4 21 3 23 15002030 5 21 4 27 15102010 6 21 6 15 15002110 7 21 7 27 15001910 2 3 3 21 3 21 4 2 4 1 2 1 2 312 4 3 1 2 3 4 2

More information

メニュー0827 +ジャムセッション

メニュー0827 +ジャムセッション M E N U Publish Bar since 1971? 850 850 900 1000 850 850 A 1000 1000 600 400 900 A & 1400 1400 1450 1550 1550 1150 1450 B & 1150 & & & & & & 1150 1200 1300 1300 900 1200 C & 1150 & & & & & & & 1150 1200

More information

22“ƒ†Q’ÓŠ¹

22“ƒ†Q’ÓŠ¹ 1 122 23 122 23 10 2 20 20 10 22 18 122 23 10 10 3 1 3 3 2 3 4 2 (e-tax) 4 1 15 1 2 3 4 6 23 122 2 3 122 23 4 4 23 122 660-8544 (06) 64161381 5 122 23 6 23 122 1400370 7 122 9 MonotaRO 23 [] ENEOS 11 30

More information

サプリメント4.PDF

サプリメント4.PDF Vol.13,No,2004 106 Oct.200Vol.13 No. ACE 1000 10mmHg ACE ACE ACE Vol.13,No.4,2004 107 L- L- EPA DHA B 2002 a. CSPHP A D E K b. TG DAG DA EPA/DHA EPA DHA n-3 n- EPA DHA n- EPA DHA Vol.13,No,2004 108 n-6

More information

経済論集 46‐1(よこ)(P)/2.三崎

経済論集 46‐1(よこ)(P)/2.三崎 1 1 14 2 1866 8 20 20 2 4 1871 20 3 4 2 1969 9 12 28 33 3 1970 35 5 1965 p.119. 1995 p.67 1960 p.86. 1965 p.120. 1927 p.5. 1942 p.127, p.129. 10 1877 7 12 16 6 10 7 10 1877 8 7 6 8 16 25 29 10 1877 9 1

More information

「若年不安定就労・不安定住居者聞取り調査」報告書

「若年不安定就労・不安定住居者聞取り調査」報告書 2008 3 2006 2007 3 19 6 7 5,400 2007 4 5 19 94 1 2 2007 5 i 2007 6 12 100 100 1 2 2008 3 ii 1960 1990 iii = 1990 = = iv 5 5 v & = 2 24 = 1990 10 vi vii i iii 1 3 1.1.............................................

More information

実効ある民生対策

実効ある民生対策 2007/9/22 http://www.kikonet.org/ 12% 2 200262008 Post 2012 3 4 500 450 400 350 300 250 C O 2 200 150 100 50 0 482t 217t 164t 127t 68t 62t 23t ( 456t 257t 238t 174t 78t 54t 37t 1990 1991 1992 1993 1994

More information

写真付全製品一覧.PDF

写真付全製品一覧.PDF 2005.5.1 3-3-3 www. makelifebetter.co.jp 30 1 7 22253 11,000 PV 80 30 1 7 22252 11,000 PV 80 0603 3,130 2,500 PV17 15792 4,380 3,500 PV25 19458 3,900 3,000 PV 20 20758 4,810 3,700 PV25 15796 8,250 6,600

More information

86 7 I ( 13 ) II ( )

86 7 I ( 13 ) II ( ) 10 I 86 II 86 III 89 IV 92 V 2001 93 VI 95 86 7 I 2001 6 12 10 2001 ( 13 ) 10 66 2000 2001 4 100 1 3000 II 1988 1990 1991 ( ) 500 1994 2 87 1 1994 2 1000 1000 1000 2 1994 12 21 1000 700 5 800 ( 97 ) 1000

More information

救急車同乗実習レポート 総括

救急車同乗実習レポート 総括 14 9 1 9 10 10 19:00 23:00 52 1 6.5 40 CT X CT Ope 15 /min BP 100/70mmHg HR 96 /min O U m 60 25/min BP 140/80mmHg HR 55 O Spo 98 BP 172/68mmHg O 30 15 /min BP 100/60mmHg HR 80 /min BS O O CO 30 40 JCS

More information

医療レーザー脱毛の威力と限界

医療レーザー脱毛の威力と限界 .... mm. CT WH W H W H W H... kcalkcal. 1. cal kcal 1 6 2 3. 4. 5. 1 6 6. B6 B12 B. BMI BMI30 C. D. kg mm . CT WH W H W H W H... kcalkcal . 1. cal kcal 1 6 2 3. 4. 5. 1 6 6. B6 B12 B. BMI BMI30 C. D.

More information

特許権侵害に対する損害賠償額の算定に関する裁判例の動向

特許権侵害に対する損害賠償額の算定に関する裁判例の動向 [*361] 1998 1999 102 1 105 3 102 3 102 1 102 2 102 3 1. 2. 102 1 2.1 2.2 2.3 2.4 3. 102 2 3.1 3.2 4. 102 3 5. 1. 1) 102 1990 3 1 102 1 10 102 2 102 2 10 102 3 [*362] 2) 1998 1999 102 1 105 3 102 3 2 3)

More information

薬局におけるインシデント事例の集計・分析結果

薬局におけるインシデント事例の集計・分析結果 13 11 14 31 13 11 14 31 13 11 14 31 10 13 13 e-mail 18 4,000 13 14 H13.4.1 11.17 11.18 H14.3.31 13 14 31-1- 600 400 (18.4 17.7 17.0 16.0 15.2 8.2 1.0 2 11 10 12 15 3 1015203040 69.5 7.8 22.7 4 (42.5) 34.3

More information

株式会社テーオーシー

株式会社テーオーシー 8841 39 164117331 1 1 3 TOC TOC TOC 5 39 7 9 1 11 12 13 14 TOC 17331 39 164117331 176 TOC 45TOC 11,m 2 17,m 2 IT 3 75 1 TOC 15 1 TOC TOC TOC1 83, TOC TOC 37123TOC TOC3 TOC 2TOC 2 4 TOC 2 3 TOC 21 26 26

More information